As of 2024-12-13, the EV/EBITDA ratio of Pliant Therapeutics Inc (PLRX) is -3.61. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PLRX's latest enterprise value is 793.30 mil USD. PLRX's TTM EBITDA according to its financial statements is -219.95 mil USD. Dividing these 2 quantities gives us the above PLRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.6x - 13.7x | 12.1x |
| Forward P/E multiples | 18.9x - 31.3x | 20.8x |
| Fair Price | (67.43) - (48.71) | (58.65) |
| Upside | -586.9% - -451.7% | -523.5% |
| Date | EV/EBITDA |
| 2024-12-12 | -3.58 |
| 2024-12-11 | -3.70 |
| 2024-12-10 | -3.79 |
| 2024-12-09 | -3.88 |
| 2024-12-06 | -3.84 |
| 2024-12-05 | -3.73 |
| 2024-12-04 | -3.84 |
| 2024-12-03 | -3.82 |
| 2024-12-02 | -4.07 |
| 2024-11-29 | -3.59 |
| 2024-11-27 | -3.52 |
| 2024-11-26 | -3.47 |
| 2024-11-25 | -3.50 |
| 2024-11-22 | -3.37 |
| 2024-11-21 | -3.33 |
| 2024-11-20 | -3.30 |
| 2024-11-19 | -3.31 |
| 2024-11-18 | -3.18 |
| 2024-11-15 | -3.21 |
| 2024-11-14 | -3.33 |
| 2024-11-13 | -3.58 |
| 2024-11-12 | -3.60 |
| 2024-11-11 | -3.79 |
| 2024-11-08 | -3.92 |
| 2024-11-07 | -3.98 |
| 2024-11-06 | -4.12 |
| 2024-11-05 | -3.90 |
| 2024-11-04 | -3.78 |
| 2024-11-01 | -3.79 |
| 2024-10-31 | -3.67 |
| 2024-10-30 | -3.76 |
| 2024-10-29 | -3.85 |
| 2024-10-28 | -3.89 |
| 2024-10-25 | -3.69 |
| 2024-10-24 | -3.56 |
| 2024-10-23 | -3.71 |
| 2024-10-22 | -3.82 |
| 2024-10-21 | -3.83 |
| 2024-10-18 | -3.98 |
| 2024-10-17 | -3.83 |
| 2024-10-16 | -3.96 |
| 2024-10-15 | -3.65 |
| 2024-10-14 | -3.57 |
| 2024-10-11 | -3.55 |
| 2024-10-10 | -2.98 |
| 2024-10-09 | -2.95 |
| 2024-10-08 | -2.88 |
| 2024-10-07 | -2.85 |
| 2024-10-04 | -2.96 |
| 2024-10-03 | -2.85 |